ProCE Banner Activity

CABINET: Subgroup Analysis of Cabozantinib vs Placebo After ≥1 Prior Line of Therapy in Advanced Extrapancreatic Neuroendocrine Tumors Arising in GI Tract

Conference Coverage
Slideset

In this subgroup analysis of the CABINET trial, patients with advanced extrapancreatic neuroendocrine tumors arising in the GI tract and ≥1 prior line of therapy derived a significant PFS benefit with cabozantinib vs placebo.

Released: February 07, 2025

Expiration: August 06, 2025

Share

Provided by

rovided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation